3MVL image
Entry Detail
PDB ID:
3MVL
Keywords:
Title:
P38 Alpha Map Kinase complexed with pyrrolotriazine inhibitor 7K
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2010-05-04
Release Date:
2010-10-13
Method Details:
Experimental Method:
Resolution:
2.80 Å
R-Value Free:
0.33
R-Value Work:
0.22
R-Value Observed:
0.23
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Mitogen-activated protein kinase 14
Chain IDs:A, B
Chain Length:366
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-Methylphenylamino)-5-Methyl-Npropylpyrrolo[1,2-F][1,2,4] Triazine-6-Carboxamide (Bms-582949), a Clinical P38 Map Kinase Inhibitor for the Treatment of Inflammatory Diseases
J.Med.Chem. 53 6629 6639 (2010)
PMID: 20804198 DOI: 10.1021/jm100540x

Abstact

The discovery and characterization of 7k (BMS-582949), a highly selective p38α MAP kinase inhibitor that is currently in phase II clinical trials for the treatment of rheumatoid arthritis, is described. A key to the discovery was the rational substitution of N-cyclopropyl for N-methoxy in 1a, a previously reported clinical candidate p38α inhibitor. Unlike alkyl and other cycloalkyls, the sp(2) character of the cyclopropyl group can confer improved H-bonding characteristics to the directly substituted amide NH. Inhibitor 7k is slightly less active than 1a in the p38α enzymatic assay but displays a superior pharmacokinetic profile and, as such, was more effective in both the acute murine model of inflammation and pseudoestablished rat AA model. The binding mode of 7k with p38α was confirmed by X-ray crystallographic analysis.

Legend

Protein

Chemical

Disease

Primary Citation of related structures